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Advanced Review
Particle-induced pulmonary acute
phase response may be the causal
link between particle inhalation
and cardiovascular disease
Anne T. Saber,1 Nicklas R. Jacobsen,1 Petra Jackson,1
Sarah Søs Poulsen,1 Zdenka O. Kyjovska,1 Sabina Halappanavar,2
Carole L. Yauk,2 Håkan Wallin1,3 and Ulla Vogel1,4∗
Inhalation of ambient and workplace particulate air pollution is associated with
increased risk of cardiovascular disease. One proposedmechanism for this associa-
tion is that pulmonary inﬂammation induces a hepatic acute phase response, which
increases risk of cardiovascular disease. Induction of the acute phase response is
intimately linked to risk of cardiovascular disease as shown in both epidemiological
and animal studies. Indeed, blood levels of acute phase proteins, such as C-reactive
protein and serum amyloid A, are independent predictors of risk of cardiovascu-
lar disease in prospective epidemiological studies. In this review, we present and
review emerging evidence that inhalation of particles (e.g., air diesel exhaust par-
ticles and nanoparticles) induces a pulmonary acute phase response, and propose
that this induction constitutes the causal link between particle inhalation and risk
of cardiovascular disease. Increased levels of acute phase mRNA and proteins in
lung tissues, bronchoalveolar lavage ﬂuid and plasma clearly indicate pulmonary
acute phase response following pulmonary deposition of different kinds of parti-
cles including diesel exhaust particles, nanoparticles, and carbon nanotubes. The
pulmonary acute phase response is dose-dependent and long lasting. Conversely,
the hepatic acute phase response is reduced relative to lung or entirely absent. We
also provide evidence that pulmonary inﬂammation, as measured by neutrophil
inﬂux, is a predictor of the acute phase response and that the total surface area
of deposited particles correlates with the pulmonary acute phase response. We
discuss the implications of these ﬁndings in relation to occupational exposure to
nanoparticles. © 2014 The Authors.WIREs Nanomedicine and Nanobiotechnology published by Wiley
Periodicals, Inc.
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INTRODUCTION
Epidemiological studies provide strong evidence tosupport a link between exposure to particulate air
pollution and risk of cardiovascular disease.1–3 For
example, in a natural intervention study in Ireland, a
ban on coal sales for heating in private households led
to a reduction in the level of black smoke from 50.2
to 14.6 μg/m3.3 The reduction in black smoke was
accompanied by a 10.3% (95% CI 8–13) reduction in
deaths associated with cardiovascular events. An asso-
ciation has also been established between air pollution
and blood levels of C-reactive protein (CRP, a marker
of acute phase response, inflammation, and cardiovas-
cular effects) in a cross-sectional study.4 In APOE −/−
mice fed a Western diet, a model for atherosclerosis,
pulmonary exposure to ambient air particles, welding
fumes, and nanoparticles increased plaque progression
in aorta.5–8 Thus, evidence indicates that pulmonary
exposure to particles in air pollution increases cardio-
vascular risk. Increased industrial use of nanotechnol-
ogy, in particular nanoparticles, has raised the specific
concern that (occupational) exposure to nanoparti-
cles may increase risk cardiovascular disease.9 Knowl-
edge of the mechanism of action driving the hazardous
effects associated with nanoparticle exposure would
enable assessment of the magnitude of this risk and
identify possible preventive strategies.
The acute phase response is the primary alarm
response induced in the body by a variety of factors
including bacterial infections, trauma, and surgery.10
The acute phase response and accompanying increased
levels of acute phase proteins in blood are risk fac-
tors for cardiovascular disease.11–13 Conditions that
lead to increased acute phase response are associated
with increased risk of cardiovascular disease in epi-
demiological studies.14–16 For example, periodontal
pathogen and viral infections are associated with risk
of cardiovascular disease17,18; periodontal infection
has been shown to induce acute phase response and
to accelerate plaque progression in APOE −/− mice.19
Overall, it is established that blood levels of the acute
phase proteins CRP and serum amyloid A (SAA) are
predictive of future cardiovascular disease in prospec-
tive studies.20–22
Various investigators have proposed that the
mechanism underlying the association between acute
phase response and cardiovascular effects involves
the inhalation of particles leading to pulmonary
inflammation and subsequent systemic circulation of
cytokines, which in turn induce a hepatic acute phase
response.13,23–25 We have studied the possible adverse
effects resulting from inhalation or pulmonary depo-
sition of diesel exhaust particles and nanomaterials in
mice for several years.26–42 Over the course of this
research we have been unable to detect the induction
of any hepatic acute phase response by analysis of
liver mRNA or protein levels of acute phase genes in
mice exposed by inhalation to diesel exhaust particles
or carbon black particles in our own experiments.43
Instead, our results demonstrates that inhalation of
particles induces a strong pulmonary acute phase
response. In the present review article we discuss our
alternative proposed mechanism of action govern-
ing an association between pulmonary acute phase
response and cardiovascular disease, and the resulting
implications.
ACUTE PHASE RESPONSE
The acute phase response is characterized by altered
blood levels of acute phase proteins including CRP,
SAA, and fibrinogen10 (Figure 1) and (Box 1).
Although this pathway is generally conserved across
mammals, there are some notable differences; in par-
ticular, noteworthy differences exist between humans
and mice. In mice, Saa3 is expressed in various tissues
including the lung, whereas Saa1 and Saa2 are con-
sidered liver specific.44 In contrast, in humans SAA3
is a pseudogene,45 and SAA1 and SAA2 are expressed
hepatically and extra-hepatically.46 Moreover, Crp
is only moderately induced by inflammatory stimuli
in mice.47,48 Thus, these differences must be taken
into consideration when extrapolating results derived
from mouse models to humans.
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FIGURE 1 | Characteristic patterns of change in plasma
concentrations of some acute-phase proteins after a moderate
inﬂammatory stimulus. (Reprinted with permission from Ref 10.
Copyright 1999, Massachusetts Medical Society)
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BOX 1
PHYSIOLOGICAL FUNCTIONS OF THE
ACUTE PHASE RESPONSE
The acute phase response is deﬁned as the
systemic changes induced by cytokines released
from inﬂamed areas. It is termed the acute
phase response even though it accompanies
both acute and chronic inﬂammation. The acute
phase response is characterized by changes
in the concentration of plasma proteins, the
so-called acute phase proteins (e.g., SAA and
CRP). In addition, the acute phase response is
accompanied by other acute phase phenomena.
These include changes at the neuroendocrine,
hematopoietic, metabolic, and hepatic level,
among others. Examples of neuroendocrine
changes are fever, somnolence, and anorexia.
Hematopoietic changes include anemia and
leuco- and thrombocytosis, while examples
of metabolic changes are osteoporosis and
decreased gluconeogenesis.
The acute phase response is believed to
be beneﬁcial. For example, the opsonization
of microorganisms by CRP makes it easier for
macrophages to recognize and engulf invad-
ing microorganisms. Another example is somno-
lence, which is a characteristic in patients with
inﬂammatory conditions. The reduced energy
demand associated with somnolence is beneﬁ-
cial in disease states. However, when the inﬂam-
matory condition and the accompanying acute
phase response become chronic, it may cause
adverse effects. Secondary amyloidosis is the
result of an accumulation of SAA in individu-
als with chronic inﬂammatory disorders. Another
example of a non-beneﬁcial effect of a chronic
acute phase response is anemia.
Since plasma concentrations of acute phase
proteins reﬂect the level of inﬂammation these
are used clinically to evaluate the progression
of disease and to predict risk of future dis-
ease. Increasing evidence suggest that some of
these changes are causal and not just passive
bystanders of disease.
Based on Gabay and Kushner.10
PULMONARY ACUTE PHASE
RESPONSE
Although the acute phase response is defined by
changes in blood concentrations of specific proteins,
the cellular origin of these proteins is not well
characterized. The underlying assumption has been
that they are of hepatic origin.12,22–24 We assessed
transcriptional changes in acute phase response
genes to determine the origin of the acute phase
response in mice. Inhalation and instillation of var-
ious particles, including carbon black and TiO2
nanoparticles, diesel exhaust particles, dust samples
and both single and multiwalled carbon nanotubes,
induced a pulmonary acute phase response, whereas
the hepatic response was barely detectable or entirely
absent.11,28,35,39,40,43,49 Studies supporting this finding
are shown in Table 1. For example, in one study mice
were exposed daily for 1 h by inhalation to 40 mg/m3
nano TiO2 over 11 consecutive days. This daily dose
corresponds to half the dose of an 8-h working day
at the Danish Occupational Exposure limit of 10
mg/m3. Mice were sampled 5 days after the final dose.
Global transcriptional profiling in these mice revealed
that the acute phase genes Saa3, Saa1, and fibrino-
gen were the most differentially expressed genes in
lung.39 The acute phase response was dose-dependent;
higher doses led to statistically significantly greater
gene expression of more acute phase genes and to a
dose-dependent increase in the expression of the acute
phase genes at the mRNA level. In another study
mice were sampled 24 h after intratracheal instillation
of nano-TiO2; we observed statistically significant
increases in 8, 21, and 44 acute phase response genes
in the low (18 μg/mouse), medium (54 μg/mouse), and
high (162 μg/mouse) dose groups in lung tissue using
a 1.3 fold change as a cut-off.28 The same pattern
was observed applying a 1.5-fold cut-off (Table 1).
In all of the studies, Saa3 was the most upregulated
acute phase gene and in many cases was also the most
differentially expressed gene. Consequently, we have
used Saa3 mRNA levels as a biomarker of pulmonary
acute phase response.11,27,28,39,40,42 This analysis
showed that a clear dose-dependency is observed in
the expression levels of Saa3 mRNA. For example,
24 h after intratracheal instillation of nano-TiO2,
Saa3 mRNA levels increased by 1.8-fold for the low,
87-fold for the medium and 368-fold for the high
dose groups11 (Table 1). The duration of the acute
phase responses was dose- and particle-dependent.
The largest response was observed 1 day post expo-
sure for most particles, and the response declined
over time. However, mice exposed to carbon black at
the medium and high dose (54 μg and 162 μg/mouse)
exhibited 5-fold and 22-fold increases in pulmonary
Saa3 mRNA levels compared to vehicle-exposed
controls, respectively, 28 days after the exposure.11
These doses correspond to 3 or 9 days of exposure to
Printex 90 carbon black at the current Danish occu-
pational exposure limit to carbon black (3.5mg/m3),
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TABLE 1 Differential Expression of Murine Acute Phase Genes and Saa3 Expression Levels after Exposure to Different Nanomaterials and at
Different Time Points
Post Exposure Day 1 3 28
Dose/Animal 18 μg 54 μg 162 μg 18 μg 54 μg 162 μg 18 μg 54 μg 162 μg Ref
TiO2 nanoparticles
N acute phase genes1 0 5 10 3 1 3 1 2 3 28
Fold increase of Saa3 mRNA2 1.8 87 368 1.1 2.6 19 1 1.8 5.5 11
Carbon Black nanoparticles
N acute phase genes1 0 7 10 0 0 4 0 0 2 42
Fold increase of Saa3 mRNA2 63 237 294 8.3 24 51 1.1 5 22 11
Multiwalled Carbon nanotubes
N acute phase genes1 5 5 10 ND ND ND ND 1 ND 35
Fold increase of Saa3 mRNA2 52 151 95 39 152 612 7.9 29 88 11
ND, not determined.
1The number of differentially expressed acute phase genes as observed in DNA microarray. Murine acute phase genes were identified through the Gene category
on NCBI. The following genes were included: ACADM, AHSG, ANGPTL4, APEX1, CD163, CREB3L3, CRP, CSF3, EPO, ESRRA, F2, F8, FGF21, FN2,
HAMP,HNF4A,HP, IL1RN, IL22, IL6, IL6ST, INS2, ITIH4, LBP, LCN2,MRGPRA3,NR1H4,NR5A2,ORM1,ORM2, PRLR,REG3A,REG3B,REG3G,
RELA, SEPP1, SERPINA1B, SERPINA3N, SERPINF2, SIGIRR, SIM2, SMAD3, STAT3, STAT5B, SULT2A1, SAA1, SAA2, SAA3, SAA4, SAAL3, TSC2, and
VIMP. Genes with a fold change±1.5 and FDR P-values≤0.05 were considered as differentially expressed.
2Fold increase of mRNA Saa3 was determined using qRT-PCR. Saa3 levels were normalized to 18S levels.
respectively. For nano-TiO2, Saa3 mRNA was only
statistically significantly up-regulated after 28 days for
the highest dose (162 μg/mouse). The studies described
above clearly demonstrate that pulmonary transcrip-
tional changes in the acute phase response are induced
following particle inhalation and remain elevated for
a prolonged period of time.
Induction of pulmonary acute phase response
has also been demonstrated at the protein level
in mice. For example, SAA3 protein levels mea-
sured by Western blotting were increased 2.2 fold
in lung tissue 5 days after inhalation exposure
to nano-TiO2.
39 SAA levels were also elevated in
bronchoalveolar fluid and plasma after intratra-
cheal instillation of multiwalled carbon nanotubes.11
Protein levels of two other acute phase proteins,
granulocyte colony-stimulating factor (GCSF), and
granulocyte-macrophage colony-stimulating-factor
(GM-CSF), were increased 6-fold and 2.5-fold,
respectively, in lung tissue 24 h after instillation of
nanosized TiO2
28 and 3-fold and 1.3-fold increased,
respectively, 26–27 days after instillation of nanosized
carbon black.29 In both cases, GCSF protein levels
increased in a dose-dependent manner. Moreover,
dose-dependent increases in the protein levels of
IL-1𝛽, IL-6, and CXCL1 were also found in lung tis-
sues 26–27 days after instillation of nanosized carbon
black.29 Teeguarden et al. reported increased protein
levels of the acute phase proteins C3, Fn1, S100A8
and S100A9 in the lung tissues of mice exposed
to single-walled carbon nanotubes by aspiration.50
Moreover, the level of the acute phase protein hap-
toglobin was increased in BALF 24h after a single
intratracheal instillation of 200 μg nanosized carbon
black/mouse.51 These observed protein level changes
are consistent with, and support, the large changes
observed in the transcriptional network of acute phase
response genes in lung tissues. Moreover, it is worth
noting that changes in pulmonary expression of acute
phase response genes are correlated with increased
concentrations of acute phase proteins in systemic
circulation. Elevated SAA levels were found in plasma
both 1 and 28 days after intratracheal instillation of
nanosized carbon black42 and 3 days following pul-
monary exposure to multiwalled carbon nanotubes.11
Overall, the results described above indicate
that expression changes in pulmonary acute phase
response genes are the strongest measured response
following pulmonary exposure to nanoparticles. The
acute phase response has been demonstrated at both
the transcript and protein level in lung tissue, bron-
choalveolar lavage fluid and in plasma. Finally, the
response is dose-dependent and long lasting at doses
that are comparable to relatively short exposures at
the current Danish Occupational Exposure Limits for
carbon black and TiO2.
PULMONARY ACUTE PHASE
RESPONSE CORRELATES
WITH NEUTROPHIL INFLUX
AND SURFACE AREA OF DEPOSITED
PARTICLES
We recently reported a close correlation between
Saa3 mRNA levels in lung tissue and the number
520 © 2014 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals, Inc. Volume 6, November/December 2014
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of neutrophil cells in bronchoalveolar lavage fluid
(Figure 2).11 This is in agreement with the observation
that SAA is a strong neutrophil chemoattractant.52,53
Pulmonary Saa3 mRNA is a biomarker of a pul-
monary acute phase response. Therefore, this corre-
lation has important implications. Neutrophil influx
has been shown to correlate with the total sur-
face area of deposited nanoparticles in the lung.54,55
By extension, this necessitates that the pulmonary
acute phase response correlates with the total sur-
face area of the deposited particles in the lung; this
is shown for pulmonary instillation of TiO2 and car-
bon black nanoparticles 1 and 28 days after instilla-
tion (Figure 3(a) and (b)). Thus, inhalation of smaller
particles will cause a larger acute phase response per
mass unit of deposited particles than larger particles.
The total surface area increases proportionally to the
decrease in diameter, such that a 10-times reduction
in particle size results in 10-times larger total surface
area per mass unit. In addition, nanoparticles deposit
deeper in the respiratory tract than larger particles
and therefore have longer retention time. Therefore,
smaller particles produce prolonged inflammation in
terms of neutrophil influx and prolonged acute phase
response compared to larger particles.11,23,34 In accor-
dance with this, pulmonary acute phase response was
evident 28 days after exposure to nanosized TiO2,
nanosized carbon black, SWCNT and MWCNT and
about four weeks after inhalation exposure to nano-
sized TiO2 and carbon black.
11 Thus, the total sur-
face area of all deposited particles correlates with
neutrophil influx and with pulmonary acute phase
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FIGURE 2 | Correlation between neutrophil inﬂux and normalized
Saa3 mRNA levels in lung tissue 1–28 days following instillation or
inhalation of various nanomaterials or dust collected at a biofuel plant.
Saa3 mRNA levels were quantiﬁed by real-time PCR and normalized to
18S. Exposures include inhalation of carbon black and TiO2
nanoparticles (open squares), instillation of carbon black and TiO2
nanoparticles (ﬁlled diamonds), instillation of carbon nanotubes (ﬁlled
circles), instillation of biofuel dust (ﬁlled triangles), instillation of vehicle
(negative control) (ﬁlled squares). (Reprinted with permission from Ref
11. Copyright 2013 under Creative Commons Attribution License)
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FIGURE 3 | Correlation between neutrophil inﬂux and total surface
area of deposited nanoparticles. Doses of 0, 18, 54, or 162 μg/mouse
carbon black or TiO2 nanoparticles were deposited in lungs of mice by
intratracheal instillation and the number of neutrophils in bronchial
lavage ﬂuid was determined as described previously.74 N = 6 per group,
except for vehicle controls where n= 22: (a) 24 h after instillation and
(b) 28 days post exposure.
response. Because acute phase response predicts future
cardiovascular risk, these findings establish a direct
link between the total surface area of pulmonary
deposited particles and cardiovascular risk.
LITTLE OR NO HEPATIC ACUTE PHASE
RESPONSE
The hepatic acute phase response following inhalation
or pulmonary instillation of nanoparticles is much
smaller than the observed pulmonary acute phase
response, or may even be entirely absent. Indeed,
no hepatic acute phase response was detected by
global gene expression analysis following inhalation
exposure to 20mg/m3 carbon black or diesel exhaust
particles 90min daily for 4 consecutive days.11,43
In contrast, Saa3 mRNA levels were increased
4.4- and 17.4-fold in lung tissue following inhala-
tion of nanosized carbon black and diesel exhaust
particles, respectively.11 Similarly, little or no hepatic
acute phase response was found following instillation
of nanosized carbon black as determined by Saa3
mRNA levels,11,41,42 and no hepatic acute phase
Volume 6, November/December 2014 © 2014 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals, Inc. 521
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response was found after instillation of multiwalled
carbon nanotubes, even when the Saa3 levels in lung
tissue were induced 600-fold.11
Erdely et al. exposed mice to different kinds
welding fume particles by aspiration at a dose of
340 μg/mouse.56 They found up to 15-fold increases
in the levels of Saa1 in liver 24 h post exposure. They
did not assess Saa1 or Saa3 expression in lung tissue.
The used dose was almost twice the dose in our stud-
ies (162 μg/mouse). The welding fume particles were
larger than the TiO2 nanoparticles and since specific
surface areas were not specified, dose comparison in
terms of surface area is not possible. We observed a
268-fold increased Saa3 expression in lung tissue 24 h
after exposure to the 162 μg TiO2 nanoparticles and
a 10-fold lower 30-fold increase in expression of the
chemokine Ccl2 which was also assessed by Erdely.28
Erdely et al. found up to 58-fold increased Ccl2
expression.56 Provided that gene expression patterns
in response to welding fumes are somewhat similar
to that observed for TiO2 nanoparticles, we would
predict that pulmonary Saa3 expression could be up
to 600-fold increased following exposure to welding
fumes. Thus, the hepatic acute phase response would
be small compared to the pulmonary acute phase
response.
Overall, the studies described above indicate that
pulmonary exposure to particles leads to a large and
robust pulmonary acute phase response and, to a
much lesser degree, to a hepatic acute phase response.
MICRORNA EXPRESSION IN LUNG
TISSUE
It was recently suggested that microRNAs (miRNAs)
may be involved in controlling acute phase response
following influenza infection in pigs.57 MiRNAs were
differentially expressed in lung tissue 1, 3, or 14
day after aerosol exposure to H1N2 influenza virus.
Among the perturbed miRNAs, miR-21 levels were
increased 2-fold 3 days after the exposure. MiR-21
was predicted to target CXCL10, IL12A, IL10, IL1B,
and SAA. Interestingly, miR-21 expression levels were
also increased 1.5-fold in lung tissue in mice 5
days after inhalation exposure to TiO2
39 and 2-fold
26–28 days after instillation or inhalation of car-
bon black nanoparticles.41 Among the proposed tar-
gets for miR-21, increased protein levels of IL12,
IL10, IL1B, and SAA have been found in lung tis-
sue after pulmonary exposure to TiO2 and carbon
black nanoparticles.11,28,49 Among the other differ-
entially expressed miRNAs observed, only increased
expression of miR-223 was found both after inhala-
tion of TiO2 in mice and inhalation of influenza
virus in pigs.39,57 The miRNA showing the clearest
dose-response relationship following TiO2 and car-
bon black nanoparticle exposure is miRNA-135b.39,41
MiR-135b was recently shown to be regulated by
IL-1-receptor activation.58 More studies are needed to
understand the role of miRNAs in nanotoxicology.
CHOLESTEROL HOMEOSTASIS AFTER
PULMONARY PARTICLE DEPOSITION
Induction of acute phase response affects choles-
terol homeostasis. Cholesterol synthesis mainly takes
place in the liver and cholesterol circulates in the
blood as part of high density (HDL) and low den-
sity (LDL) lipoprotein molecules. In keeping with
this, induction of the acute phase response in mice
leads to profound changes in cholesterol biosynthe-
sis and in blood levels of lipids.42,59 In a study where
the acute phase was induced by subcutaneous injec-
tion of silver nitrate, blood levels of HDL cholesterol
and LDL/VLDL cholesterol increased and followed
the same time course trajectory as the acute phase
response (Figure 4).59 During particle-induced pul-
monary acute phase by carbon black, plasma levels
of HDL decreased 3 and 28 days post exposure and
plasma levels of LDL increased 28 days post exposure
compared to vehicle-exposed control animals.42 Fur-
thermore, cholesterol biosynthesis was upregulated in
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FIGURE 4 | Change in plasma total cholesterol (solid squares), free
cholesterol (open squares), and cholesterol esters (solid circles)
concentrations following the induction of an acute subcutaneous
inﬂammatory reaction with 2% silver nitrate. Values are the
mean± SEM, n= 12. (Reprinted with permission from Ref 59. Copyright
1997, Elsevier)
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both liver and lung at the level of gene expression.42
Hepatic cholesterol levels were 12–22% increased, but
the effect was not statistically significant (P= 0.06).42
Therefore, it seems that in mice the increased blood
levels of cholesterol have at least two sources. During a
hepatic acute phase response, cholesterol biosynthesis
is upregulated in liver. In addition, a lowered reverse
cholesterol transport will also decrease the excretion
of cholesterol through the bile and thus contribute to
increases in blood cholesterol levels.59
Mice and humans are expected to differ in blood
lipid response because mice lack the cholesterol ester
transfer protein that transfers cholesterol esters from
HDL to LDL.59 When humans undergo acute phase
response, LDL synthesis is increased, but LDL levels
in blood decrease due to upregulation of LDL receptor
activity.60 HDL blood levels decrease, and blood
levels of triglycerides increase.60 Patients with acute
myocardial infarction undergo acute phase response.
Cholesterol biosynthesis was assessed in 34 patients
hospitalized with acute myocardial infarction and
cholesterol biosynthesis was found to be 23 and
29% increased 1 and 2 days after hospitalization,
respectively.11,61
Thus, cholesterol biosynthesis is consistently
increased during an acute phase response, and
increased cholesterol biosynthesis may take place in
lung and liver.
SAA EXPRESSION
SAA may play a central role in promoting atheroscle-
rosis and thus risk of cardiovascular disease. As
described above increased expression of three iso-
genes, Saa3, Saa1, and Saa2, was observed following
pulmonary exposure to nanoparticles in mice.39,42
The same response was observed when mice inhaled
lipopolysaccharide (LPS) over 20 min,62 which mim-
ics a lung bacterial infection. Gene expression changes
quantified 1, 2, 4, 8, 12, and 24 h post exposure to LPS
showed evidence of an early inflammatory response,
measured as increased expression of macrophage
inflammatory genes, which peaked 1 h post exposure.
This was followed by induction of proinflammatory
interleukin and chemokine genes, which peaked 2
or 4 h post exposure. Among these, IL1-𝛽, Il-6 and
TNF are strongly induced and peak 2–4 h after LPS
exposure.62 IL-1𝛽, IL-6, and TNF all induce Saa
transcription.52 The expression of Saa1 and Saa3
was already increased just 1 h after exposure, but the
increased expression peaked 12 h post exposure.62
Thus, pulmonary Saa expression is likely induced by
proinflammatory cytokines and Saa expression peaks
later than proinflammatory cytokine expression, ie
after 12 h following LPS challenge and somewhat
later following particle exposure.
A number of cell types present in the lung are
capable of expressing SAA including macrophages,63
Clara cells,64 and alveolar type II cells.64 Macrophages
are capable of expressing Saa1, Saa2, and Saa363 and
all three SAA proteins are incorporated into HDL after
induction of acute phase response.63 The exact cellular
origin of the pulmonary acute phase response is not
at present clear, although several cell types that are
present in the lungs are capable of expressing SAA.
SAA PROTEIN FUNCTION IN HDL
SAA likely promotes cardiovascular disease
directly. When SAA expression is induced dur-
ing the acute phase response, SAA replaces
ApolipoproteinA-1 in HDL, resulting in partial
depletion of ApolipoproteinA-1 from HDL.65,66
ApolipoproteinA-1 is a cofactor for lecithin-
cholesterol acyltransferase (LCAT), which esteri-
fies cholesterol for transport. Thus, SAA indirectly
influences cholesterol efflux through its effects on
ApolipoproteinA-1.59 In addition, SAA has been
shown to directly inhibit LCAT activity.67 In a study
of patients with acute coronary syndrome, stable
coronary artery disease and healthy controls, serum
levels of ApolipoproteinA-1 were the best predictor
of cholesterol efflux compared to total cholesterol,
triglycerides, HDL, LDL, ApoB, CRP, and SAA.68
Thus, incorporation of SAA into HDL leads to accu-
mulation of cholesterol in the peripheral tissues at
least partly caused by reduced cholesterol efflux.
When macrophages are exposed to SAA-
containing HDL, they turn into foam cells in a dose-
dependent manner69 as a consequence of increased
uptake of LDL69 and increased uptake and hydrolysis
of cholesteryl esters from SAA-containing HDL.70
Foam cells are cholesterol-loaded macrophages that
are a principal component of plaques. It has been
demonstrated that virus-mediated overexpression of
Saa1 was sufficient to promote plaque progression in
APOE −/− mice.71
SAA seems to signal by Toll-like receptor 4 to
activate NF-k𝛽-dependent transcription72 and induces
IL-1 and IL-8 in neutrophil cells (which accumu-
late during pulmonary inflammation). It promotes
monocyte chemotaxis and adhesion, and induces
matrix-metalloproteinases.73 In addition, SAA poten-
tiates prothrombotic and proinflammatory events by
induction of tissue factors.73
Therefore, formation of acute phase HDL
lipoproteins that contain more SAA and less
ApolipoproteinA-1 may constitute an important
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link between acute phase response and cardiovascu-
lar disease. The acute phase HDL is less proficient
in reverse cholesterol transport, thereby leading to
perturbed cholesterol homeostasis and increased accu-
mulation of cholesterol. In addition, macrophages
exposed to SAA or acute phase HDL change behavior
and turn into foam cells, thus further promoting
plaque progression and atherosclerosis.
A MECHANISM
FOR PARTICLE-INDUCED
PULMONARY ACUTE PHASE
RESPONSE AND ATHEROSCLEROSIS
On the basis of the data presented above, we
propose a mechanism of action that may con-
tribute to particle-induced acute phase response
and increased risk of cardiovascular disease
(Figure 5).
Inhalation of particles induces a pulmonary
acute phase response, which depends on the total sur-
face area of the deposited particles and the clearance
1 Inhalation of particles
Heart
3
2
Macrophage Foam cell
SAA-DHL
SAA-HDL
APOA1-HDLSAAAPR
Liver
Lung
PMN
FIGURE 5 | The proposed mechanism of action of particle-induced
cardiovascular disease. Inhalation of particles (indicated by 1 in the
ﬁgure) leads to a pulmonary acute phase response (2).
The accumulation of SAA in lungs leads to attraction of neutrophils.
SAA is incorporated into HDL (3), replacing APO-A1 and goes into
systemic circulation. SAA-HDL is deﬁcient in reverse cholesterol
transport and promotes foam cell formation from macrophages, leading
to plaque progression.
of the particles from the alveoli. Nanoparticles have
a large surface to mass ratio and prolonged reten-
tion in lung; therefore, inhalation of nanoparticles
induces a strong and prolonged acute phase response.
The cholesterol biosynthetic pathway is upregulated
at the level of transcription in the lung and/or liver. In
the alveoli, macrophages engulf particles and produce
SAA, once induced by proinflammatory cytokines.
The excreted SAA functions as a neutrophil attrac-
tant in the lung, resulting in neutrophil influx into the
lung. SAA is incorporated into HDL where it replaces
ApolipoproteinA-1. SAA probably goes into systemic
circulation as SAA-HDL. There are no indications that
the macrophages residing in the lung enter the sys-
temic circulation, since macrophages in blood smears
from mice following pulmonary exposure to carbon
black do not contain carbon black nanoparticles in
contrast to macrophages isolated from bronchiolar
lavage fluid (LM Pedersen, P Jackson, H Wallin, and
U Vogel, unpublished observations). Lee et al. recently
proposed a role for SAA-HDL in the pathogenesis of
atherosclerosis.69 They note that normal HDL inhibits
foam cell formation by facilitating cholesterol efflux
from macrophages and participates in reverse choles-
terol transport, enabling cholesterol excretion.69 In
contrast, the combined absence of Apo-A1 and pres-
ence of SAA leads to lowered reverse cholesterol
transport from peripheral tissues by HDL and fur-
thermore SAA-HDL stimulates foam cell formation
of peripheral macrophages.69 In addition, SAA stimu-
lates MMP9 expression in monocytes. MMP9 triggers
atherosclerotic rupture possibly leading to myocardial
ischemia.69 There is no direct evidence that pulmonary
acute phase response and pulmonary Saa expres-
sion cause plaque progression; however, we have
shown that pulmonary exposure to TiO2 nanoparti-
cles will promote plaque progression7 and in paral-
lel that both inhalation39 and pulmonary exposure by
instillation11,28,74 of the very same TiO2 nanoparticles
induces pulmonary acute phase response while caus-
ing very little or no hepatic acute phase response.11
Thus, the downstream consequences of induced acute
phase response and increased SAA expression may
be promotion of foam cell formation and plaque
progression.
LIFESTYLE FACTORS THAT AFFECT
ACUTE PHASE RESPONSE IN HUMANS
Some lifestyle factors influence SAA levels. Body
mass index (BMI) is highly associated with plasma
SAA levels21 because white adipocytes express SAA.75
SAA transcription is induced by the proinflammatory
cytokines IL6, IL1𝛽, and TNF. Alcohol suppresses
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LPS-induced SAA production in mice.76 A possible
mechanism may be an ethanol-mediated inhibition of
NLRP3 inflammasome activation in macrophages,77
thus inhibiting IL-1𝛽 mediated activation of Saa tran-
scription. If this is an important mechanism for the
protective effect of alcohol in relation to acute coro-
nary heart disease,78 then alcohol intake should have
the largest effect among smokers and others exposed
to acute phase response inducers. In a study of 2989
men, the effect of smoking and alcohol intake on coro-
nary artery occlusion was assessed.79 The observed
protective effect of alcohol intake on artery occlusion
was largest among heavy smokers and least among
non-smokers. However, there was no statistically sig-
nificant interaction. Non-steroidal anti-inflammatory
drug (NSAID) use also inhibits induction of proinflam-
matory cytokines, and thus likely inhibits the acute
phase response. In line with this view, aspirin has
a protective effect against future myocardial infarc-
tion especially among those with high baseline CRP
levels.80 Furthermore, it has been shown that the
NSAID ibuprofen inhibits IL1B synthesis and amy-
loidosis in a mouse model of Alzheimer’s disease.81
Taken together, this indicates that controlled human
exposures ideally should take alcohol consumption,
BMI and NSAID use into account. Thus, it may prove
more difficult to detect increases in acute phase protein
levels in people with suppressed acute phase response
caused by low-level aspirin, pain-killers, or high alco-
hol consumption.
CONTROLLED HUMAN EXPOSURES
A number of controlled human exposures to various
kinds of particles have been performed where blood
markers of inflammation and acute phase response
have been assessed. Only a few of these studies have
assessed SAA levels, whereas more have examined
CRP. In cross-sectional studies, CRP and SAA levels
are highly correlated.20,21 However, since there are
differences in the kinetics of CRP and SAA syn-
thesis and degradation, there may be differences in
controlled human studies. None of the controlled
exposures assessed exposure to engineered nanopar-
ticles. However, we propose that the total surface
area of pulmonary deposited particles will predict
the pulmonary acute phase response. Therefore, we
hypothesize that inhalation of all kinds of particles
will induce a pulmonary acute phase response in a
dose-dependent manner.
Blood levels of CRP are associated with risk
of coronary heart disease in prospective studies, but
genetically determined differences in CRP levels are
not associated with risk.82 This indicates that CRP is
not causally related to risk of coronary heart disease,
but rather co-varies with the causal factor, which could
be SAA.82,83
The influence of particle exposure on serum
levels of acute phase proteins has been addressed in a
number of controlled human exposure studies. Here,
we summarize some of these.
Both SAA and CRP were assessed in a con-
trolled human exposure study using a 4-h exposure
to 0.24–0.28mg/m3 wood smoke where about half
the particles were less than 100 nm.84 The 13 test
subjects were healthy non-smokers who did not
consume excessive amounts of alcohol, exhibited no
allergic symptoms and were free of infections over the
week prior to the experiment.84 Blood levels of SAA
were 2-fold increased 3 and 24 h after the exposure,
whereas no changes were detected for CRP. Exposure
to clean air had no effect on either acute phase protein
at any time point.84
The effects of wood smoke exposure were
assessed in a random cross over study.82 Portable
air filters were used to clean the air in households
with wood-stoves during two 7-day periods, one with
HEPA filtration and one without. HEPA filtration
of the air reduced particulate matter 2.5 microns in
diameter and less (PM2.5) from 11.3 to 4.6 μg/m3. In
this study the participants were non-smokers. CRP
levels were assessed after 7-day exposures and a
32.6% reduction in CRP levels was observed after
HEPA filtration of the air.85 SAA levels were not
assessed in this study.
In a second random cross-over study on 42
non-smoking elderly volunteers, indoor air was either
HEPA filtrated or unfiltered for 48 h.86 HEPA filtra-
tion reduced PM2.5 from 9.4 to 4.6 μg/m3. SAA and
CRP were assessed in blood sampled in the morning
following each 48-h exposure scenario. No changes
were observed for either SAA or CRP.
In a study of occupational exposure to welding,
cutting, grinding, and foundries, the mean level of
total dust was 0.93mg/m3 with PM2.5 0.31mg/m
3.87
CRP levels (but not SAA levels) were assessed at
four time-points: pre-shift, and post-shift day 1, day
2, and day 4. Pre-shift was on the first day after
summer vacation. There were 73 subjects and smoking
was the only factor taken into account. Twelve of
seventy-three were current smokers. CRP levels were
19% increased post-shift day 2 but not altered on
post-shift days 1 or 4.
Fifty-two elderly persons with ischemic heart
disease were followed for six months and CRP levels
were correlated with ambient air pollution.88 The
average ambient PM2.5 was 8.7 μg/m3. SAA was not
assessed. CRP levels were statistically significantly
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associated with PM2.5, with the strongest associations
observed with 1 and 2 lag days.
Twelve male patients with stable coronary heart
disease and 12 age-matched volunteers were exposed
to concentrated ambient fine and ultrafine particles
for 2 h in a randomized double-blinded cross-over
design.89 Participants were non-smokers and were
asked to abstain from alcohol intake 24 h before expo-
sure. All twelve coronary heart disease patients took
aspirin. The PM2.5 level was 190 μg/m3. Individuals
exposed to clean air had PM2.5 levels of 0.5 μg/m3.
CRP levels were unaffected by exposure after 6 and
24 h. SAA was not assessed.
Taken together, some but not all controlled
exposure studies find increased levels of SAA and/or
CRP after inhalation exposure to particles. In general,
increased levels of acute phase proteins were found
in studies with either larger particle doses, longer
durations or which included test subjects who did not
take medication that could interfere with acute phase
response. Thus, evidence from available controlled
human exposures partly supports the notion of acute
phase response as a possible mediator of systemic
effects following particle inhalation. However, the
human exposures provide no information regarding
the tissue of origin of the acute phase proteins.
ENDOTHELIAL DYSFUNCTION
Inhalation of particles promotes cardiovascular dis-
ease by other means in addition to the acute phase
response, and pulmonary acute phase response likely
also promotes cardiovascular risk by other means in
addition to the proposed acute phase HDL model.
Endothelial dysfunction has been proposed
as a pro-atherosclerotic mechanism of particle
inhalation.90 In very elegantly designed experiments,
it was shown that serum from volunteers exposed to
diesel exhaust particles was able to increase expres-
sion of vascular cell adhesion molecule (VCAM-1) in
primary human coronary artery endothelial cells.90
This identified ‘a circulating factor’ as the mediator of
the particle-induced endothelial dysfunction. In a sub-
sequent and equally elegant study,91 CD36 +/+ and
−/− mice were exposed to ozone, and vasorelaxation
was assessed in aorta from unexposed mice exposed
to serum ex vivo as a measure of endothelial dysfunc-
tion. Neutrophil influx was observed in CD36+/−
mice but not in Cd36−/− mice. It was shown that
while the CD36 receptor was not required for pro-
duction of the circulating factor, CD36 was required
for impairment of vasorelaxation responses. CD36 is
a SAA receptor92 and it is expressed on macrophages
and on endothelial cells.91 SAA has been shown to
induce endothelial dysfunction.93 Thus, the study by
Robertson91 suggests that ozone inhalation induces
a pulmonary acute phase response independently of
CD36 status, and that SAA-containing acute phase
HDL or SAA alone are possible soluble factors medi-
ating the CD36-dependent endothelial dysfunction
(Box 1).
CONCLUSION
In this review we summarize evidence that pulmonary
exposure to particles and nanoparticles induces a pul-
monary acute phase response in mice, whereas acute
phase response is reduced or absent in the liver fol-
lowing particle inhalation. We suggest that the acute
phase response, and in particular SAA, may contribute
significantly to the pathogenesis of cardiovascular dis-
ease. We suggest that SAA is produced in the lungs and
enters systemic circulation as part of acute phaseHDL.
Acute phase HDL is deficient in reverse cholesterol
transport, and stimulates foam cell formation from
macrophages in peripheral tissues leading to plaque
formation.
There is overwhelming evidence that the acute
phase response is causally related to risk of cardiovas-
cular disease from both epidemiological studies and
mechanistic studies in vivo and in vitro. Thus, the
fact that pulmonary exposure to particles induces pul-
monary acute phase response in mice and accompa-
nying systemic circulation of acute phase protein pro-
vides evidence of a causal link between particle inhala-
tion and risk of cardiovascular disease. The associa-
tion is further supported by controlled human expo-
sure studies demonstrating increased blood levels of
acute phase proteins following exposure to different
kinds of particles. Acute phase proteins in systemic
circulation can originate from many different tissues
and therefore only increased tissue transcription can
be used as evidence of origin. In addition, we suggest
a mechanism involving SAA related foam cell forma-
tion, which would also explain the lack of association
between genetically determined differences in CRP lev-
els and risk of coronary heart disease.
Our finding of an association between neu-
trophil influx and pulmonary acute phase response
has important implications. Neutrophil influx has also
been shown to correlate closely with the total sur-
face area of deposited particles. This implies that
inhalation of nanosized particles would induce a much
stronger acute phase response and that the accompa-
nying risk of cardiovascular disease should be pro-
portional to the increase in total surface area com-
pared to the same mass of larger particles. This is
especially relevant in relation to the consideration
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of nanoparticle-specific occupational exposure levels,
and underscores cardiovascular disease as an occupa-
tional disease. In epidemiological studies, even modest
differences in blood levels of CRP and SAA are asso-
ciated with risk of future cardiovascular disease11–13
and ambient air pollution was found to correlate
with CRP levels.88 Taken together, this could indi-
cate that even ambient levels of particles such as those
in air pollution may evoke a pulmonary acute phase
response and modify risk of cardiovascular disease
correspondingly.
Further work is required to establish the slope
of the correlation between deposited surface area and
acute phase proteins levels in blood, to more defini-
tively establish the correlation between acute phase
protein levels in blood and future risk of cardiovascu-
lar risk. In addition, the findings and proposed mod-
els provide the basis for the development of in vitro
testing protocols if macrophage-SAA synthesis can be
used to group and rank particles (including nanopar-
ticles) for their potential to cause cardiovascular risk.
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